Linked Life Data

20388340

Source:http://linkedlifedata.com/resource/pubmed/id/20388340

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-4-14
pubmed:abstractText
There are various therapies for the treatment of macular edema secondary to retinal vein occlusion (RVO). Intravitreous injection of anti-vascular endothelial growth factor (VEGF) is a new procedure. The efficacy and safety of this therapy have been widely proved in short term clinical observations. However, the relapse of macular edema and the requirement for multi-injections are still remaining problems. It requires more evidences to prove that a better long term prognosis could be obtained from this procedure as compared with traditional laser coagulation. The optimizing therapies should include a combination of anti-VEGF therapy with other drugs and laser treatment to decrease the risk of multi-injections and to obtain the best results. Selection of appropriate therapeutic procedure (based on the evidence based medicine) to protect and improve visual function are the important project of clinicians and require further exploration and investigation.
pubmed:language
chi
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0412-4081
pubmed:author
pubmed:issnType
Print
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
100-2
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Be cautious of using anti-vascular endothelial growth factor therapy for treatment of macular edema secondary to retinal vein occlusion].
pubmed:affiliation
First People's Hospital of Shanghai Jiaotong University, Shanghai 200080, China. sun_xiaodong@hotmail.com
pubmed:publicationType
Journal Article, English Abstract